{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:55:56Z","timestamp":1790207756265,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejca.2025.115432","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T15:06:51Z","timestamp":1744988811000},"page":"115432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers"],"prefix":"10.1016","volume":"222","author":[{"given":"Cristina","family":"Smolenschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6180-4815","authenticated-orcid":false,"given":"Anna","family":"Lancry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2746-9402","authenticated-orcid":false,"given":"Elodie","family":"Klajer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Debaillon-Vesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Marie","family":"Vantelon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Boileve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Valery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-7551","authenticated-orcid":false,"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3304-2106","authenticated-orcid":false,"given":"Marie","family":"Decraecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115432_bib1","article-title":"Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: a nationwide retrospective analysis","volume":"15","author":"Neuzillet","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.ejca.2025.115432_bib2","unstructured":"SPF. Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 et 2018 - Tumeurs solides: \u00c9tude \u00e0 partir des registres des cancers du r\u00e9seau Francim."},{"key":"10.1016\/j.ejca.2025.115432_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2025.115432_bib4","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ejca.2025.115432_bib5","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ejca.2025.115432_bib6","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s11523-023-01007-y","article-title":"Durvalumab: a review in advanced biliary tract cancer","volume":"18","author":"Fung","year":"2023","journal-title":"Target Oncol"},{"key":"10.1016\/j.ejca.2025.115432_bib7","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2025.115432_bib8","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/hep.29764","article-title":"Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma","volume":"68","author":"Nepal","year":"2018","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.ejca.2025.115432_bib9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2017.10.013","article-title":"Precision medicine for patients with advanced biliary tract cancers: an effective strategy within the prospective MOSCATO-01 trial","volume":"87","author":"Verlingue","year":"2017","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.ejca.2025.115432_bib10","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2025.115432_bib11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejca.2025.115432_bib12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejca.2017.05.006","article-title":"Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?","volume":"81","author":"Verlingue","year":"2017","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.ejca.2025.115432_bib13","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4087","article-title":"Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH)","volume":"37","author":"Javle","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115432_bib14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastas-- Rev"},{"key":"10.1016\/j.ejca.2025.115432_bib15","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115432_bib16","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115432_bib17","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2\u2013positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115432_bib18","article-title":"Management of intrahepatic and perihilar cholangiocarcinomas: Guidelines of the French Association for the Study of the Liver (AFEF)","author":"Neuzillet","year":"2024","journal-title":"Liver Int J Int Assoc Study Liver"},{"key":"10.1016\/j.ejca.2025.115432_bib19","unstructured":"Cancer des voies biliaires | SNFGE. 2023."},{"key":"10.1016\/j.ejca.2025.115432_bib20","article-title":"Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study","volume":"39","author":"Meric-Bernstam","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115432_bib21","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115432_bib22","article-title":"Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study","volume":"42","author":"Pant","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115432_bib24","unstructured":"ZIIHERA (zanidatamab) - Cancer des voies biliaires. Haute Aut. Sant\u00e9."},{"key":"10.1016\/j.ejca.2025.115432_bib25","article-title":"Real-world impact of matched targeted therapy on survival in advanced biliary tract cancer: An international collaborative study","author":"Hoyek","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115432_bib26","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115432_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with her2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115432_bib28","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12885-022-09351-4","article-title":"Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients","volume":"22","author":"Horimoto","year":"2022","journal-title":"BMC Cancer"},{"issue":"1394","key":"10.1016\/j.ejca.2025.115432_bib29","article-title":"An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity","volume":"14","author":"Weisser","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2025.115432_bib30","doi-asserted-by":"crossref","unstructured":"Guardia G.D.A., Anjos C.H. dos, Rangel-Pozzo A., Santos F.F. dos, Birbrair A., Asprino P.F., et al. Beyond HER2 expression in breast cancer: Investigating alternative splicing profiles as a mechanism of resistance to anti-HER2 therapies. 2024.","DOI":"10.1101\/2024.11.25.24317569"},{"key":"10.1016\/j.ejca.2025.115432_bib31","article-title":"HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy","volume":"8","author":"Triulzi","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejca.2025.115432_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104003","article-title":"ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer","author":"Vogel","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2025.115432_bib34","unstructured":"Enhertu demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumours. 2023."},{"key":"10.1016\/j.ejca.2025.115432_bib35","article-title":"Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: current advancements and future perspectives","volume":"199","author":"Ten Haaft","year":"2024","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.ejca.2025.115432_bib36","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4006","article-title":"Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): an investigator-initiated multicenter phase 2 study (HERB trial)","volume":"40","author":"Ohba","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T11:58:07Z","timestamp":1749815887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925002138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":34,"alternative-id":["S0959804925002138"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115432","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115432"}}